Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: "Depomed, Inc." (DEPO) Report Updated: Feb 08, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Depomed, Inc." (DEPO)

Rating: Buy Volatility: Moderate
Total Grade: B Industry: Pharmaceuticals
Competitors: JNP, HSKA, AXN, SUPN

Stock Analysis

Rating: Monthly View

February March April May June July August September October November December January

Rating: Weekly View

This Week: B down upgrade
Last Week: C same downgrade
Two Weeks Ago: B up upgrade
service keys

"Depomed, Inc."© quotemedia

Company Profile

Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products for neurology, pain, and other central nervous system conditions and diseases. The company offers Gralise tablet, a once-daily formulation of gabapentin for the management of postherpetic neuralgia; Zipsor, an oral liquid filled capsule formulation of diclofenac potassium for the treatment of mild to moderate acute pain; and Glumetza metformin hydrochloride extended release tablet that are used as a once-daily treatment for adults with type 2 diabetes. Its product pipeline also comprises Serada, which completed three Phase III clinical trials for the treatment of menopausal hot flashes; and DM-1992 that is in Phase II clinical trials for the treatment of Parkinson's disease. The company sells its Gralise products to wholesalers and retail pharmacies. It has collaboration or license arrangements with Merck & Co., Inc.; Boehringer Ingelheim International GMBH; Ironwood Pharmaceuticals, Inc.; Janssen Pharmaceutica N.V.; Covidien, Ltd.; Patheon Puerto Rico, Inc.; Valeant Pharmaceuticals International, Inc.; and PharmaNova, Inc. The company was founded in 1995 and is based in Menlo Park, California.

Recent News: "Depomed, Inc."